39 results about "Canine adenovirus" patented technology

Recombinant adenoviruses, methods of making them, uses for them, including in immunological, immunogenic, vaccine or therapeutic compositions, or, as a vector for cloning, replicating or expressing DNA and methods of using the compositions and vector, expression products from them, and uses for the expression products are provided. More particularly, recombinant canine adenoviruses (CAV) and methods of making them, uses for them, expression products from them, and uses for the expression products, including recombinant CAV2 viruses are provided. Additionally, truncated promoters, expression cassettes containing the promoters, and recombinant viruses and plasmids containing the promoters or expression cassettes are provided.

Disclosed and claimed are methods of non-invasive genetic immunization in an animal and/or methods of inducing a systemic immune or therapeutic response in an animal, products therefrom and uses for the methods and products therefrom. The methods can include contacting skin of the animal with a vector in an amount effective to induce the systemic immune or therapeutic response in the animal. The vector can include and express an exogenous nucleic acid molecule encoding an epitope or gene product of interest. The systemic immune response can be to or from the epitope or gene product. The nucleic acid molecule can encode an epitope of interest and/or an antigen of interest and/or a nucleic acid molecule that stimulates and/or modulates an immunological response and/or stimulates and/or modulates expression, e.g., transcription and/or translation, such as transcription and/or translation of an endogenous and/or exogenous nucleic acid molecule; e.g., one or more of influenza hemagglutinin, influenza nuclear protein, influenza M2, tetanus toxin C-fragment, anthrax protective antigen, anthrax lethal factor, rabies glycoprotein, HBV surface antigen, HIV gp 120, HIV gp 160, human carcinoembryonic antigen, malaria CSP, malaria SSP, malaria MSP, malaria pfg, and mycobacterium tuberculosis HSP; and/or a therapeutic, an immunomodulatory gene, such as co-stimulatory gene and/or a cytokine gene. The immune response can be induced by the vector expressing the nucleic acid molecule in the animal's cells. The animal's cells can be epidermal cells. The immune response can be against a pathogen or a neoplasm. A prophylactic vaccine or a therapeutic vaccine or an immunological composition can include the vector. The animal can be a vertebrate, e.g., a mammal, such as human, a cow, a horse, a dog, a cat, a goat, a sheep or a pig; or fowl such as turkey, chicken or duck. The vector can be one or more of a viral vector, including viral coat, e.g., with some or all viral genes deleted therefrom, bacterial, protozoan, transposon, retrotransposon, and DNA vector, e.g., a recombinant vector; for instance, an adenovirus, such as an adenovirus defective in its E1 and/or E3 and/or E4 region(s). The method can encompass applying a delivery device including the vector to the skin of the animal, as well as such a method further including disposing the vector in and/or on the delivery device. The vector can have all viral genes deleted therefrom. The vector can induce a therapeutic and/or an anti-tumor effect in the animal, e.g., by expressing an oncogene, a tumor-suppressor gene, or a tumor-associated gene. Immunological products generated by the expression, e.g., antibodies, cells from the methods, and the expression products, are likewise useful in in vitro and ex vivo applications, and such immunological and expression products and cells and applications are disclosed and claimed. Methods for expressing a gene product in vivo and products therefor and therefrom including mucosal and/or intranasal administration of an adenovirus, advantageously an E1 and/or E3 and/or E4 defective or deleted adenovirus, such as a human adenovirus or canine adenovirus, are also disclosed and claimed.

This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention relates to vaccines and methods for protecting dogs against disease caused by Leptospira bratislava. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona.

The invention discloses a set of multiplex polymerase chain reaction (PCR) detection primers for detecting canine distemper virus, canine parvovirus, type I canine adenovirus and type II canine adenovirus. The primers comprise three pairs of primers, wherein sequences of primers for detecting canine distemper virus are shown as SEQ ID NO:1 and SEQ ID NO:2; sequences of primers for detecting canine parvovirus are shown as SEQ ID NO:3 and SEQ ID NO:4; and sequences of primers for detecting type I canine adenovirus and type II canine adenovirus are shown as SEQ ID NO:5 and SEQ ID NO:6. The primers can simultaneously detect canine distemper virus, canine parvovirus, type I canine adenovirus and type II canine adenovirus through a multiplex PCR method, and have the advantages of high specificity, high sensitivity, high repeatability and the like.

The invention provides a method for labeling antibodies by colorful fluorescent granules and a test paper strip prepared from the antibodies. Animal viruses including, but not limited to, canine distemper viruses, canine parvoviruses, canine adenoviruses, canine coronavirus, rabies viruses, feline leukemia viruses, Marek's disease viruses, Newcastle disease viruses and the like are used as targets, and the corresponding antibodies labeled by colorful fluorescent micro-spheres are prepared by the aid of chemical covalent processes and can be applied to detecting the animal viruses. The method for labeling the antibodies by the colorful fluorescent granules and the test paper strip prepared from the antibodies have the advantages that colorful detection lines with bright developed colors can appear during detection, and accordingly qualitative results can be obtained; the contents of the animal viruses in samples further can be subsequently quantitatively obtained, accordingly, test results are clear and are high in stability, and the test paper strip can be stored at the room temperature for a long time.

The present invention relates to the field of CAdV vector vaccines, and especially to promoters suitable to express target antigens from such vector vaccines. Disclosed and claimed are recombinant canine adenoviruses, methods of making them, uses for them (including in immunological, immunogenic, vaccine or therapeutic compositions, or, as a vector for cloning, replicating or expressing DNA and methods of using the compositions and vector), expression products from them, and uses for the expression products. Additionally, disclosed and claimed are truncated EHV4 promoters, expression cassettes containing the promoters, and recombinant viruses and plasmids containing the promoters or expression cassettes.

The present invention discloses a recombinant canine adenovirus-2 transfer vector, a method for constructing the recombinant canine adenovirus-2 transfer vector and an applications thereof. The recombinant canine adenovirus-2 transfer vector loses the 1412bp fragment of the E3 region, a large fragment of exogenous gene can be inserted, and moreover, a hCMV IE promoter, a multiple cloning site, an enhanced green fluorescent protein gene and a SV40 early transcribed Poly A signal sequence can be inserted in the position of the lost fragment of the E3 region. The method successfully constructs the lost recombinant CAV-2 transfer vector of the E3 region, obtains a purified canine adenovirus-2 strain containing EGFP reporter gene and optimizes the cloning and purification method thereof, an evaluation indicates that the biological property of the recombinant virus is stable, and therefore the present invention provides a technical platform for the further development of CAV-2 live vector vaccine and related fundamental researches.

The invention provides a variable region sequence of a mouse monoclonal antibody specifically bound to a CAV (canine adenovirus) and an antibody specifically bound to the CAV. The antibody can be usedfor preparing a kit and pharmaceutical composition. According to the kit, the problem of low detection sensitivity in the prior art is solved, leak detection and false negative are avoided, various targets can be detected, and the kit has the advantages of being rapid, simple and accurate; the pharmaceutical composition can effectively prevent and treat disease caused by CAV-1 and CAV-2.

The invention belongs to the technical field of bioengineering. The invention relates to recombinant protein. The recombinant protein comprises two dominant epitopes of canine adenovirus II protein. In order to improve the yield of the recombinant protein in a prokaryotic expression system, preferred codons of escherichia coli are adopted to convert an amino acid sequence of the recombinant protein into a corresponding nucleotide sequence, the nucleotide sequence is chemically synthesized and a recombinant expression vector is constructed. The invention also relates to a method for establishing a phage library by immunizing a mouse with the recombinant protein. A corresponding canine adenovirus II protein single-chain antibody scfv sequence is obtained through panning and screening; the obtained scfv sequence is constructed into a complete mouse IgG1 antibody sequence expression vector; a monoclonal antibody is expressed by transiently transferring HEK293F cells; the monoclonal antibody is purified and europium ions (Eu<3+>) are marked; and an optimal monoclonal antibody pairing combination is determined through orthogonal experiments and can be used for early diagnosis of canine infectious laryngotracheitis and pneumonia.

The invention provides a group of nucleic acids for synchronously detecting and distinguishing five canine diarrhea viruses and also provides a multi-gene-chip high-flux molecular biological detectionmethod for the five canine diarrhea viruses. The nucleic acids include upper and lower primers and hybridization probes of a canine adenovirus type 1, a canine adenovirus type 2, canine coronaviruses, canine distemper viruses and canine parvoviruses of the five canine diarrhea viruses. By adopting the method, multi-gene-chip detection is performed by extracting the nucleic acids of the canine diarrhea viruses in samples to be detected, synchronous and accurate detection and distinguishing of the canine diarrhea viruses in samples to be detected are achieved, and the nucleic acids have the advantages of being good in specificity, high in sensitivity, good in stability, simple and convenient to operate and capable of achieving high-flux quick detection.

The invention provides a variable region sequence of a mouse monoclonal antibody specifically bound with CAV-1 (Canine Adenovirus type I) Fiber protein, and an antibody specifically bound with the CAV-1 Fiber protein, wherein the antibody can be used for preparing a kit and a pharmaceutical composition. The kit provided by the invention overcomes the problem of low detection sensitivity in the prior art, avoids the occurrence of phenomena of missed detection and false negative, can detect various targets of dogs with high sensitivity, and can detect various targets of non-dog animals with highsensitivity; the kit has the advantages of rapidness, simpleness, convenience and accuracy; the pharmaceutical composition of the invention can effectively prevent and treat diseases caused by the CAV-1.

The invention discloses a canine adenovirus type-1 (CAdV-1) antibody ELISA detection kit and application thereof. According to the detection kit, a pCold II prokaryotic expression system is utilized to prepare a PB (penton base) and Knob protein with good reactogenicity, the PB and the Knob protein are subjected to a large quantity of induced expressions, two types of protein after renaturation are used as envelop antigens respectively and compared with a purified CAdV-1 totivirus, and finally the Knob protein is determined as the optimal ELISA envelop antigen. On this basis, the ELISA detection kit with high efficiency, good sensitivity and good specificity for a CAdV-1 serum antibody is provided; results of simultaneous sample detection through the detection kit and an SN method show that the sensitivity of the ELISA detection kit is 97.14%, the specificity is 90.00%, and the SN coincidence rate is 93.57%; and the detection kit has the advantages of high sensitivity, good specificity, strong repeatability and the like.

The invention provides a variable region sequence of a mouse monoclonal antibody specifically binding to canine adenovirus type 2 fiber protein, and an antibody specifically binding to canine adenovirus type 2 fiber protein conformational epitope. The antibody can be used for preparing kits and pharmaceutical compositions. The kit provided by the invention overcomes the problem of low detection sensitivity in the prior art, avoids missing detection and false negative phenomena, can detect various targets, and has the advantages of rapidness, simplicity, convenience and accuracy; and the pharmaceutical composition disclosed by the invention can be used for effectively preventing and treating diseases caused by CAV-2.

The invention discloses a recombinant vaccine with canine adenovirus type-2 as a live vector for displaying a protective antigen of rabies virus, which relates to recombinant vaccines displaying the protective antigen or an antigenic epitope of the rabies virus respectively by utilizing the characteristics of different structural proteins of the canine adenovirus type-2. The protective antigen of the rabies virus or a ribonucleotide sequence expressing the antigenic epitope are inserted at a hydrophobic locus of a structural protein gene to ensure that an exogenous antigen or an antigenic epitope is subject to fusion expression with structural protein of the exogenous antigen or the antigenic epitope on the surfaces of adenoviruses. After the recombinant vaccines challenge, test animals are subject to closed and isolated rearing, feeding and disease conditions of the test animals are observed and recorded; and the results show that dogs taking any kind of recombinant vaccine by oral administration and intramuscular injection all can resist the attack of strong viruses, and the survival rate is more than 90 percent.

The invention discloses a heat-resistant protective agent for a canine distemper, canine parvovirus, canine adenovirus and canine parainfluenza quadruple live vaccine as well as a preparation method and application of the heat-resistant protective agent and belongs to the technical field of heat-resistant protective agents for live vaccines in the field of biological medicines. The heat-resistantprotective agent comprises 7%-10% of cane sugar, 3%-4% of gelatin, 8%-10.0% of trehalose, 6%-8% of peptone, 2%-4% of glycine and 4%-6% of PEG, the components are simple, the raw materials are easy toobtain, the preparation method is simple, and the heat-resistant protective agent can effectively reduce the loss of various virus antigens in the freeze-drying process when used for preparing thecanine distemper, canine parvovirus, canine adenovirus and canine parainfluenza quadruple live vaccine, and can ensure the immune efficacy and long-term stable storage of the canine distemper, canine parvovirus, canine adenovirus and canine parainfluenza quadruple live vaccine.